- Home
- IBIO vs FLGC Comparison
IBIO vs FLGC Comparison
Compare IBIO & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- FLGC
- Stock Information
- Founded
- IBIO 2008
- FLGC 2019
- Country
- IBIO United States
- FLGC United States
- Employees
- IBIO N/A
- FLGC N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- FLGC Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- FLGC Health Care
- Exchange
- IBIO Nasdaq
- FLGC Nasdaq
- Market Cap
- IBIO 15.9M
- FLGC 15.9M
- IPO Year
- IBIO N/A
- FLGC 2021
- Fundamental
- Price
- IBIO $0.81
- FLGC $0.69
- Analyst Decision
- IBIO Strong Buy
- FLGC Buy
- Analyst Count
- IBIO 3
- FLGC 2
- Target Price
- IBIO $4.87
- FLGC $4.00
- AVG Volume (30 Days)
- IBIO 5.4M
- FLGC 104.1K
- Earning Date
- IBIO 05-02-2025
- FLGC 08-11-2025
- Dividend Yield
- IBIO N/A
- FLGC N/A
- EPS Growth
- IBIO N/A
- FLGC N/A
- EPS
- IBIO N/A
- FLGC N/A
- Revenue
- IBIO $375,000.00
- FLGC $53,260,000.00
- Revenue This Year
- IBIO $36.00
- FLGC N/A
- Revenue Next Year
- IBIO N/A
- FLGC N/A
- P/E Ratio
- IBIO N/A
- FLGC N/A
- Revenue Growth
- IBIO 650.00
- FLGC N/A
- 52 Week Low
- IBIO $0.64
- FLGC $0.42
- 52 Week High
- IBIO $6.89
- FLGC $2.11
- Technical
- Relative Strength Index (RSI)
- IBIO 47.34
- FLGC 55.93
- Support Level
- IBIO $0.71
- FLGC $0.62
- Resistance Level
- IBIO $0.87
- FLGC $0.72
- Average True Range (ATR)
- IBIO 0.08
- FLGC 0.05
- MACD
- IBIO 0.02
- FLGC 0.00
- Stochastic Oscillator
- IBIO 37.39
- FLGC 75.00
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.